A pair of four-drug interferon-based hepatitis C
regimens worked well, but further study has been halted after a few patients
experienced serious adverse events, according to a set of presentations last
week at the 48th International Liver Congress (EASL 2013) in Amsterdam. While this type of quad regimen
has little if any future, some of the component drugs remain promising.
The first direct-acting antiviral agents (DAAs) for
chronic hepatitis C were approved in 2011, changing the treatment paradigm. While
the future of therapy for most people with hepatitis C is likely to be all-oral regimens, the
first two DAAs were approved for use with, and most current candidates were
first tested with, pegylated interferon and ribavirin.